#For patients
Written for adults considering a peptide as part of their health management.
Is CJC-1295/ipamorelin flushing normal?
Facial flushing after CJC-1295 and ipamorelin injections is a known, documented reaction pattern for this peptide class, not an unusual one.
What is KLOW? The peptide blend, explained
KLOW mixes BPC-157, TB-500, GHK-Cu, and KPV. Here is what the evidence for each ingredient shows, and why none of it answers a fracture-healing question.
PT-141 for low libido on GLP-1 drugs
Reduced libido is a reported side effect on GLP-1 drugs. Here is what the evidence shows for PT-141 (bremelanotide) and kisspeptin as options for women.
Retatrutide and DKA in type 1 diabetes
A Cureus 2026 case report: a type 1 diabetes patient self-injected online-sourced retatrutide and developed impending DKA alongside a Shigella infection.
Needle reuse and vial contamination
A used needle can carry material into another vial. CDC injection-safety guidance explains why each vial entry needs new sterile equipment.
GLP-1 Drugs and Hair Loss: Cohort Evidence
A 2026 cohort study found semaglutide and tirzepatide carry higher alopecia odds than other GLP-1 drugs, with rapid weight loss as the likely driver.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.
GLP-1 Drugs and Kidney Fibrosis in Mice
A new mouse study compared semaglutide, tirzepatide and retatrutide on kidney fibrosis. Here is what the animal data does and does not show.
Semaglutide safety in dialysis patients
A 2026 Diabetes Care exchange scrutinised pooled trial data on semaglutide safety after dialysis initiation. What the numbers show and what remains open.
Can you freeze a reconstituted peptide?
A reader paused a CJC-1295/ipamorelin cycle and wanted to freeze the rest. Here is what the closest approved label and the freeze-thaw literature say.
Selank and Semax: Should You Combine Them?
Selank has real generalized anxiety disorder trial data. Semax's focus reputation does not, and no study has combined the two.
Tirzepatide vs Semaglutide: Liver Risk
A large real-world study found tirzepatide and injectable semaglutide carry the same risk of serious liver outcomes in adults with type 2 diabetes.